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Abstract 
BACKGROUND: CD10 was initially recognised as a cell–surface antigen expressed by acute lymphoblastic 
leukaemias, and hence it’s early designation as Common Acute Lymphoblastic Leukemia Antigen (CALLA). Also, 
it has been proven to be reactive in various non-lymphoid cells and tissue and different types of neoplasms.  
AIM: To evaluate the immunohistochemical expression of CD10 in malignant thyroid neoplasms and different 
benign lesions and to assess whether CD10 can be used as a malignancy marker in thyroid pathology or not. 
MATERIAL AND METHODS: A total of 83 archived, formalin fixed, paraffin embedded tissue blocks of 83 cases 
of malignant thyroid neoplasms and different benign lesions. The samples were immunohistochemically analysed 
for CD10 expression. A p-value of less than 0.05 was considered statistically significant. 
RESULTS: CD10 was expressed in 91% of the studied malignant thyroid neoplasms and 58% of benign thyroid 
lesions. It was expressed in 26 of 28 (92.9%) conventional papillary carcinomas, ten of 10 (100%) follicular 
variants of papillary carcinoma, seven of nine (77.8%) minimally invasive follicular carcinomas, two of three 
(66.7%) widely invasive follicular carcinomas, and seven of 7 (100%) undifferentiated carcinomas, seven of 11 
(66.7%) adenomatous nodules and eight of 15 (53.3%) follicular adenomas. No statistically significant correlations 
were detected between CD10 expression and patients’ age, sex, lymph node metastasis, tumour stage and 
capsular invasion. 
CONCLUSION: CD10 shows strong sensitivity (91.2%) and moderate specificity (42.3%) in the diagnosis of 
malignancy overall and shows strong sensitivity (86.4%) and moderate specificity (42.3%) in the diagnosis of 
malignancy in the follicular-patterned lesions. So, CD10 might be useful in differentiating malignant from benign 
thyroid lesions (good positive test) and in the diagnosis of follicular variant of papillary carcinoma. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Thyroid cancer represented the most common 
endocrine malignancy [1]. Thyroid carcinoma 
accounts for about 1% of all cancers, and its 
incidence has notable geographic variation [2]. 
Papillary thyroid carcinoma (PTC) is the commonest 
form of malignant thyroid tumour accounting for 75% 
to 85% of all thyroid cancer cases [3].  
There are two main obstacles to the diagnosis 
of thyroid lesions especially the follicular-patterned 
ones which encompass four entities: adenomatous 
nodule, follicular adenoma (FA), follicular carcinoma 
(FC), and follicular variant of papillary thyroid 
carcinoma (FVPTC) [4]; the discrimination of 
minimally invasive follicular carcinoma from follicular 
adenoma or adenomatous nodule and the correct 
diagnosis of follicular carcinoma [5], [6], [7]. FC is 
differentiated from FA when there is a capsular, 
vascular, or extra-thyroid invasion or if there are nodal 
or distant metastases [8]. Furthermore, the differential 
diagnosis of follicular cell-derived hyperplastic and 
neoplastic lesions may be very problematic, and the 
matter is rarely solved by immunohistochemistry [9]. 
Moreover, some of the encapsulated thyroid 
nodules showing follicular morphology may exhibit 
diffuse or focally intermediate nuclear features of 
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papillary carcinoma. Thus, it may become another 
source of controversy [10]. As long as the lesion 
shows capsular and/or vascular invasion, it is possible 
to make a diagnosis of well-differentiated carcinoma 
without further subtyping. On the contrary, if there is 
no invasion, follicular adenoma (FA) and papillary 
carcinoma follicular variant (PCFV) should be 
considered in the diagnosis. This crucial issue cannot 
be solved by morphology only and even 
immunohistochemically for some nodules. In this 
situation, these cases are stated as ‘well-differentiated 
tumour of uncertain malignant potential’ (WDTUMP) 
[10].  
Several immunohistochemical markers such 
as HBME1, CK19 and galectin 3 have been used to 
overcome this problem [10], [11]. These antibodies 
can be valuable, especially when used together, but 
all display some disadvantages and limitations [10], 
[11], [12], [13], [14], [15]. So, more reliable markers 
are still required to differentiate between benign and 
malignant thyroid neoplasms.  
Structurally, CD10 is known as a single-chain, 
90-110-kDa cell surface zinc-dependent 
metalloprotease that inactivates many bioactive 
neuropeptides [16]. Lately, it has been established to 
be reactive in various non-lymphoid cells and tissues 
and different types of neoplasms [17]. In thyroid 
pathology, it was positive in thyroid marginal zone 
non-Hodgkin lymphoma [18]. The utility of CD10 
marker in differentiating different benign and 
malignant thyroid lesions has been demonstrated in 
some reports [17], [19]. 
  
 
Material and Methods 
 
This cross-sectional study included 83 cases 
with different benign and malignant thyroid lesions 
obtained through the collection of archived paraffin 
blocks, from the Department of Pathology, Faculty of 
Medicine, Cairo University, Cairo, Egypt, during the 
period from June 2016 till September 2017. Cases 
with deficient clinical data, tiny biopsies or poorly fixed 
specimens were not included in the study. The 
medical records which included clinical and 
histopathological data such as age, gender, site and 
size of the tumours were revised. 
Each paraffin block was re-cut by rotator 
microtome at 5 µ thickness then mounted on glass 
slides to be stained by Haematoxylin and Eosin (H&E) 
for histopathological re-evaluation by two pathologists. 
Histopathologic examination of H&E stained slides 
was performed under low power than high power for 
confirming the diagnosis. Histological classification for 
thyroid tumours was done according to WHO 
classification 2004 [20]. 
Cases included 11 adenomatous nodules, 15 
follicular adenomas, 12 follicular carcinomas, 38 
papillary carcinomas and 7 undifferentiated 
carcinomas.  
Paraffin blocks were cut at 5 µ thickness then 
mounted on charged slides and stained manually for 
immunohistochemistry. The sections were 
deparaffinized in xylene, for 10 min, then dehydrated 
in descending series of ethanol (100%, 96%, 70%), 
followed by washes in TBS (0.05 mmol/L Tris-buffer 
physiological saline, pH 7.4-7.6), for 5 min.  
Antigen retrieval was achieved by heating the 
samples without boiling in 10 mmol/L sodium citrate 
buffer, pH 6.0 (200 mL) in a microwave oven. This 
treatment was conducted twice for 7 min. The 
sections were washed in TBS buffer for 30 min. 
The endogenous peroxide was blocked by 
0.3% hydrogen peroxide in methanol for 5 min. The 
sections were washed in TBS for 15 minutes. To 
inhibit non-specific background staining; the samples 
were incubated in a superblock for 5-10 minutes at 
room temperature. 
The primary antibody was monoclonal mouse 
CD10 antibody clone GM003 (Genemed, South San 
Francisco, CA, USA) was purchased from SNF 
medical Company, LOT NO.L 60125051, at 1:50 
dilution for one hour at room temperature. The dilution 
was based on dilution experiments. The antibody was 
diluted with 20 mmol/L TBS, pH 7.4 (10 mmol/L CaCl2, 
0.1% NaN3 and 1% BSA). The sections were 
incubated in the diluted antibody. The incubation took 
place in incubation boxes overnight. The secondary 
antibody (4.5 μL biotinylated anti-mouse antibody in 1 
mL of 1% BSA) was pipetted onto the sections and 
incubated in the moist box for 30 min. The secondary 
antibody was washed in TBS buffer for 15 min. 
The final staining was done in 
diaminobenzidine tetrahydrochloride (DAB) solution 
(49 mL TBS-buffer, 34 mg imidazole, 17 μL 30% 
hydrogen peroxide and 1 mL 30% DAB), for 5-15 min. 
The slides were washed with distilled water, 70% 
ethanol for 1 min, then in distilled water. The nuclei 
were stained with Mayer’s hematoxylin for 30 seconds 
as a counterstain. The extra stain was washed with 
tap water. The slides were then transferred through 
ascending ethanol series, and xylene before 
mounting. 
Positive control for cases stained for CD10 
was done using sections obtained from tonsils, which 
exhibited a strong intensity of CD10 immunostaining 
and the negative control was obtained by omitting the 
primary antibody. Tumour tissue sections were 
examined and scored under LEICA ICC50HD 
microscope at low power than high power 
magnification by two independent pathologists who 
were not informed of the histological diagnosis. The 
sections were regarded as positive when 
immunoreactivity was observed in the cytoplasm and 
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cell membrane. For each case, 10 high power fields 
were evaluated. Immunoreactivity was graded as 0 
(negative) when less than 10% of tumour cells were 
positive, 1 (weak) when 10-49% of tumour cells were 
positive and 2 (strong) when 50% or more of tumour 
cells was positive. The immunoreactivity interpreted 
based on the percentage of the stained cells 
irrespective of the intensity of the staining. 
Data were collected, coded and analysed 
using the Statistical Package for Social Science 
(SPSS version 21.0). Data presented in the form of 
mean, standard deviation and percentage. For 
categorical variables, differences were analysed using 
Chi-square (X
2
) test and Fisher’s-exact test. Cohen's 
kappa is used for measurement of the agreement. A 
p-value of less than 0.05 was considered significant. 
Sensitivity, specificity, and diagnostic accuracy were 
assessed. Sensitivity means the true positive rate; 
specificity means the true negative rate.  
 
 
Results 
 
Clinicopathological characteristics of the 
studied cases and their correlation with CD10 
expression are summarised in (Table 1). 
Table 1: Clinicopathological characteristics of the studied 
cases and its correlation with CD10 expression 
Parameter Number (%) 
CD10 
(Negative) 
expression 
CD10 
(weak) 
CD10 (strong) P value 
Age 
< 45 years 54 (65.1%) 5 (13.9%) 8 (22.2%) 23 (63.9%) 
0 .197  
≥ 45 years 29 (34.9%) 0 (0.0%) 6 (28.6%) 15 (71.4%) 
Gender 
Male  15 (18%) 0 (0.0%) 5 (45.5%) 6 (54.5%) 
0 .141  
Female 68 (82%) 5 (10.9%) 9 (19.6%) 32 (69.6%) 
Category 
Malignant 57 (68.7%) 5 (8.8%) 14 (24.6%) 38 (66.7%) 
0.001  
Benign 26 (31.3%) 11 (42.3%) 6 (23.1%) 9 (34.6%) 
Pathologic tumour stage (T) 
T1 18 (31.6%) 2 (11.1%) 3 (16.7%) 13 (72.2%) 
0 .180  
T2 20 (35.1%) 2 (10.0%) 2 (10.0%) 16 (80.0%) 
T3 16 (28.1%) 1 (6.3%) 8 (50.0%) 7 (43.8%) 
T4 3 (5.3%) 0 (0.0%) 1 (33.3%) 2 (66.7%) 
Lymph Node (LN) Metastasis 
N0 43 (75%) 5 (11.6%) 9 (20.9%) 29 (67.4%) 
0 .275  
N1 14 (25%) 0 (0.0%) 5 (35.7%) 9 (64.3%) 
Stage 
Stage I 37 (64.9%) 5 (13.5%) 8 (21.6%) 24 (64.9%) 
0.778  
 
Stage II 9 (15.8%) 0 (0.0%) 3 (33.3%) 6 (66.7%) 
Stage III 7 (12.3%) 0 (0.0%) 2 (28.6%) 5 (71.4%) 
Stage IV 4 (7.0%) 0 (0.0%) 1 (25.0%) 3 (75.0%) 
Papillary carcinoma cases 
With capsular 
invasion 
17 (44.7%) 0 (0.0%) 7 (41.2%) 10 (58.8%) 
0.2 Without 
capsular 
invasion 
21 (55.3%) 2 (9.5%) 4 (19.0%) 15 (71.5%) 
 
CD10 immunostaining was identified in 26 of 
28 (92.9%) conventional papillary carcinomas, ten of 
10 (100%) follicular variants of papillary carcinoma, 
seven of nine (77.8%) minimally invasive follicular 
carcinomas, two of three (66.7%) widely invasive 
follicular carcinomas, seven of seven (100%) 
undifferentiated carcinomas, eight of 15 (53.3%) 
follicular adenomas and seven of 11 (63.6%) 
adenomatous nodules (Table2). 
Table 2: Immunoreactivity of CD10 in each diagnostic category 
Diagnosis 
Total case 
number 
CD10 (Negative) 
expression 
CD10 
(weak) 
CD10 
(strong) 
Conventional PC 28 2 (7.1%) 8 (28.6%) 
18 
(64.3%) 
Follicular variant of PC 38 0 (0.0%) 3 (30.0%) 7 (70.0%) 
Minimally invasive FC 9 2 (22.2%) 0 (0.0%) 7 (77.8%) 
Widely invasive FC 3 1 (33.3%) 2 (66.7%) 0 (0.0%) 
Undifferentiated carcinoma 7 0 (0.0%) 1 (14.3%) 6 (85.7%) 
Follicular adenoma 15 7 (46.7%) 2 (13.3%) 6 (40.0%) 
Adenomatous nodule 11 4 (36.4%) 4 (36.4%) 3 (27.3%) 
 
Studied cases are categorised into two 
groups (benign and malignant). Ninety-one per cent of 
malignant cases showed positive CD10 expression 
and the remaining 9% showed negative CD10 
expression, while 58% of benign cases showed 
positive CD10 expression and the remaining 42% 
showed negative CD10 expression.  
To evaluate the value of CD10 
immunostaining in the diagnosis of malignancy, we 
performed sensitivity, specificity and diagnostic 
accuracy. CD10 shows strong sensitivity (91.2%), 
95% Confidence Interval (95% CI) (80.7 to 97%), 
moderate specificity (42.3%), 95% CI (23.35% to 
63.08%) and diagnostic accuracy (75.9%), 95% CI 
(65.27% to 84.62%). Cohen's k was run to determine 
if there was an agreement between CD10 and the 
diagnostic tool (by H&E). There was moderate 
agreement k = 4, p < 0.01. 
Besides, we separate a subset of 48 thyroid 
lesions with a follicular growth pattern (15 follicular 
adenomas, 12 follicular carcinomas, 11 adenomatous 
nodules and 10 follicular variants of papillary 
carcinoma). Sensitivity, specificity, and diagnostic 
accuracy of CD10 for the diagnosis of malignancy in 
these lesions were 86%, 95% CI (65.09% to 97.09%), 
42%, 95%CI (23.35% to 63.08%) , and 62.5%, 95% 
CI (47.35% to 76.05%) respectively. 
 
Figure 1: Follicular-patterned lesions; A: Follicular carcinoma 
showing strong CD10 staining (score 2+) (original magnification X 
400); B: Follicular variant of papillary carcinoma showing strong 
CD10 staining (original magnification X 400); C: Adenomatous 
nodule showing positive CD10 staining (score 2+) (original 
magnification X 100); D: Follicular adenoma showing positive CD10 
staining (score 2+) (original magnification X 100) 
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All the undifferentiated thyroid tumours and 
90% of the differentiated tumours showed positive 
CD10 staining, but there is no statistically significant 
relationship between CD10 expression and 
differentiation of thyroid tumours (p = 0.8) (Table 3). 
Table 3: Correlation of CD10 immunohistochemical expression 
with the differentiation of thyroid tumours 
Category 
CD10 
Total 
P 
value Negative Weak Strong 
Differentiated thyroid 
carcinoma 
5 (10%) 13 (26%) 32 (64%) 50 (100.0%) 
0.8 
Undifferentiated thyroid 
carcinoma 
0 (0.0%) 1 (14.3%) 6 (85.7%) 7 (100.0%) 
 
Moreover, we assess the correlation of CD10 
expression with some prognostic factors as lymph 
node metastasis, tumour stage and capsular invasion. 
No statistically significant relationships were observed 
between the previously mentioned parameters and 
CD10 expression (P-value = 0.27, 0.77, 0.2 
respectively) (Table1). 
 
Figure 2: Both differentiated (papillary and follicular carcinomas) and 
undifferentiated carcinomas showing positive CD10 staining (score 
2+); A: Conventional papillary carcinoma (original magnification X 
100); B: High power of A (original magnification X 400); C: Follicular 
carcinoma (original magnification X 100); D: Undifferentiated 
carcinoma (original magnification X 100) 
 
 
 
Discussion 
 
In this study, we aimed to assess the value of 
CD10 in differentiating benign and malignant tumours 
of the thyroid especially the follicular patterned thyroid 
nodules. 
The distinction between benign and malignant 
follicular tumours may be occasionally problematic as 
it relies mainly on the presence of capsular and/or 
vascular invasion. If the focus of invasion is small or 
not evident, right diagnosis becomes difficult. 
Furthermore, benign follicular tumours are sometimes 
misdiagnosed as follicular variants of papillary 
carcinoma. Lloyd and his colleagues assessed the 
observer variation in the diagnosis of follicular variant 
of papillary carcinoma; all ten skilled thyroid 
pathologists agreed in the diagnosis in only 39% of 
cases [21]. 
In order to overcome the previous limitations, 
several markers of malignancy such as CK19, HBME1, 
and galectin 3 have been studied in thyroid 
specimens, but unfortunately, all present some 
disadvantages and limitations [10], [11]. Also, a 
marker of malignancy may be used as a preoperative 
diagnostic tool for suspicious lesions. Thus the extent 
of surgery and the complementary treatments could 
be planned before thyroid operations. 
Originally, CD10 was thought to be a tumour-
specific antigen [22], but studies have shown that it is 
expressed by a variety of cell types including 
bronchial epithelial cells, renal proximal tubular 
epithelial cells, cultured fibroblasts, bone marrow 
stromal cells, breast myoepithelium, biliary canaliculi, 
fetal intestine, and certain solid tumours [17], [23], 
[24].  
Tomoda et al., 2003 was the first report on the 
expression of CD10 marker in thyroid neoplasms. 
They evaluated CD10 expression in 70 thyroid 
neoplasms and reported that CD10 was negative in 
benign lesions and pure papillary carcinomas but was 
positive in 80% and 77% of follicular carcinomas and 
follicular variant of PTC, respectively. They deduced 
that CD10 immunostaining could be a useful marker 
of follicular carcinoma to distinguish it from follicular 
adenoma and benign hyperplastic nodules and in 
diagnosing follicular variants of papillary thyroid 
carcinoma [17]. 
Another research was done by Yegen et al., 
who have investigated the staining pattern of CD10 in 
different benign (n = 14) and malignant (n = 61) 
thyroid lesions. They reported their results as follows: 
CD10 was negative in adenomatous nodules, 
minimally invasive follicular carcinomas and well-
differentiated carcinomas. It was positive in 
conventional papillary carcinomas (64.2%), follicular 
variants of papillary carcinoma (16.6%), papillary 
microcarcinomas (50%), widely invasive follicular 
carcinomas (11.1%) and follicular adenomas (30%). 
They concluded that, despite CD10 strong positivity in 
conventional papillary carcinoma, it could not be used 
as a useful marker for differentiating benign and 
malignant thyroid lesion [19]. 
Mokhtari and Ameri, 2014 reported a 
significant correlation between CD10 expression and 
both benign and malignant thyroid lesions (P < 0.001) 
as they found CD10 positivity in 29.9% of PTC cases, 
but in none of the thyroid benign lesions (0%) [25]. 
Chu and Arber have investigated CD10 
expression in 505 non-hematopoietic neoplasms 
A B C  
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including 55 thyroid tumors [follicular adenoma (n = 
24), papillary carcinoma (n = 10), medullary 
carcinoma (n = 16) and follicular carcinoma (n = 5)] by 
IHC. They detected that CD10 expression was 
negative in all the examined thyroid tumours [22]. 
In like manner, Yasuda et al., have studied 
the availability of CD10, as a histopathological marker, 
in different non-hematopoietic neoplasms including 
thyroid tumours. They reported that CD10 was not 
present in thyroid tumours and showed no diagnostic 
value for this group of non-hematopoietic neoplasms 
[27]. 
In contrast with the previously mentioned 
studies, we observed CD10 expression in benign 
lesions both in FA and adenomatous nodules as well 
as in carcinomas. Malignant tumours and benign 
lesions showed 91% and 58% positivity overall 
respectively. CD10 was identified in 26 of 28 (92.9%) 
conventional papillary carcinomas, ten of 10 (100%) 
follicular variants of papillary carcinoma, seven of nine 
(77.8%) minimally invasive follicular carcinomas, two 
of three (66.7%) widely invasive follicular carcinomas, 
seven of seven (100%) undifferentiated carcinomas, 
eight of 15 (53.3%) follicular adenomas and seven of 
11 (63.6%) adenomatous nodules. 
Statistically, CD10 shows strong sensitivity 
(91.2%), 95% CI (80.7 to 97%) and moderate 
specificity (42.3%), 95% CI (23.35% to 63.08%) in the 
diagnosis of malignancy overall with diagnostic 
accuracy (75.9%), 95% CI (65.27% to 84.62%). 
Furthermore, in the follicular-patterned lesions, it was 
found that sensitivity, specificity, and diagnostic 
accuracy of CD10 for the diagnosis of malignancy in 
these lesions were 86%, 95% CI (65.09% to 97.09%), 
42%, 95%CI (23.35% to 63.08%) , and 62.5%, 95% 
CI (47.35% to 76.05%) respectively. 
Our results are not consistent with the results 
of previous studies. We observed a higher frequency 
of positivity in both benign and malignant lesions. This 
discrepancy could be explained by geographic and 
genetic variability between patients, different sample 
size, technical variations and different antibodies, 
clones and brands. A well-known fact in 
immunohistochemistry is that the specificity and 
sensitivity of the antibodies may show variations with 
different clones and brands. Moreover, some studies 
did not evaluate different malignant thyroid lesions 
and did not perform CD10 sensitivity and specificity. 
The strengths of our data are the great variability of 
the thyroid lesions analysed by IHC using CD10 
expression, as well as performing its sensitivity and 
specificity in the diagnosis of thyroid lesions. 
In conclusion, CD10 is highly expressed in 
malignant tumours (95% of papillary carcinoma, 75% 
of follicular carcinomas and 100% of undifferentiated 
carcinoma. CD10 showed strong sensitivity (91.2%) 
and moderate specificity (42.3%) in the diagnosis of 
malignancy overall and showed strong sensitivity 
(86.4%) and moderate specificity (42.3%) in the 
diagnosis of malignancy in the follicular-patterned 
lesions. So, CD10 might be useful in differentiating 
malignant from benign thyroid lesions (good positive 
test) and in the diagnosis of follicular variant of 
papillary carcinoma being observed in 100% of these 
tumours. 
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